The Qatar Investment Authority, along with new and existing investors, has backed a $126m round for Germany-based CureVac, a messenger RNA (mRNA) therapy developer that is currently developing a potential Covid-19 vaccine.
Shares have been sold to institutional investors for €15.8 a share
Add-on is the first since LDC and Ares provided financing of £100m to the telecoms company in 2019
Acquisition of the fire safety systems provider is the first from the GP's €1.1bn eighth fund
Fresh capital will go towards increasing delivery speed and geographic footprint